WO2013162202A1 - Composition anti-inflammatoire comprenant un extrait de haricot utilisant la fermentation-cataplasme de fleur, et son procédé de préparation - Google Patents

Composition anti-inflammatoire comprenant un extrait de haricot utilisant la fermentation-cataplasme de fleur, et son procédé de préparation Download PDF

Info

Publication number
WO2013162202A1
WO2013162202A1 PCT/KR2013/003236 KR2013003236W WO2013162202A1 WO 2013162202 A1 WO2013162202 A1 WO 2013162202A1 KR 2013003236 W KR2013003236 W KR 2013003236W WO 2013162202 A1 WO2013162202 A1 WO 2013162202A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
inflammatory
extract
beans
flower
Prior art date
Application number
PCT/KR2013/003236
Other languages
English (en)
Korean (ko)
Inventor
심진섭
박준성
조선아
이재경
염명훈
조준철
Original Assignee
(주)아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)아모레퍼시픽 filed Critical (주)아모레퍼시픽
Publication of WO2013162202A1 publication Critical patent/WO2013162202A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to an anti-inflammatory composition
  • an anti-inflammatory composition comprising soy extract or fractions thereof as an active ingredient, and specifically, the soy extract or fractions thereof relates to a composition comprising a dipeptide having anti-inflammatory activity.
  • the skin is a part of the body that is directly exposed to the external environment. Exposure to excessive ultraviolet rays, pollutants or irritants causes skin irritation and inflammatory reactions such as erythema, edema, and itching. The skin trouble caused by the skin irritation stress is not only aesthetic problem, but also the substances produced during the inflammatory reaction incidentally cause pigmentation of the skin and promote the breakdown of the skin elastic fibers to affect the increase of skin wrinkles. Known (Toxicol In Vitro. 2004; 18: 231-43, Irritant dermatitis. 1996; pp. 87-111).
  • retinoids and fruit acids which are functional ingredients used for the purpose of exfoliation, skin wrinkle improvement and prevention, are the main substances causing troubles on the skin, and there are many limitations on the use of these substances in concentrations that can exhibit maximum efficacy.
  • the present inventors have confirmed that the extract of soybeans obtained by fermentation using flowers has anti-inflammatory effect and skin irritation-reducing effect, and completed the present invention.
  • the present invention includes a soybean extract or a fraction thereof as an active ingredient,
  • the soybean extract or a fraction thereof provides an anti-inflammatory composition containing at least 700 ⁇ g / g of the dipeptide having anti-inflammatory activity with respect to the total extract or fraction weight.
  • the present invention is a method of producing a soybean extract for anti-inflammatory, the method
  • (c) provides a manufacturing method comprising the step of extracting the fermented soybeans.
  • composition comprising the extract of Ssam fermented soybean extract of the present invention contains extremely high content of dipeptides, thereby reducing the secretion of interleukin for stimulation, and thus anti-inflammatory and skin irritation compared to general soybean extract or general soybean fermented extract. Efficacy in alleviation, and can be used in various fields such as cosmetics and medicines.
  • the present invention is a composition obtained by using flowers and beans, it is naturally friendly and has a low possibility of causing trouble due to low irritation to the skin.
  • the "flower” is not limited in its kind, and specifically, brown, chrysanthemum, kwanhwa, kanto, lump, gold and silver, painting, homegrown, painting, magnolia, wheat dream, windproof, balsam, pomegranate , Line drawing, line drawing, songhwa, god, softening, Wonhwa, Kwakhwa, gunhwa, phoenix and honghwahwa may be one or more selected from the group consisting of, but is not limited thereto.
  • Pueraria lobata is a dye plant that yields green color and can be used to medicate each part of the pan.
  • Brown root the root of ⁇ , contains isoflavones, which is effective for fever and sweating.
  • Gall flower is a flower of ⁇ . It is used for headache, fever and excessive chest pain due to excessive drinking, soreness of the limbs, and thirst, anorexia, bloating, and vomiting.
  • Chrysanthemum ( Dendranthema grandflorum ) is a dried flower of persimmon or white chrysanthemum, also called Jinguk , Geumjeong, and cut flowers. Chrysanthemum has a fever in the chest and is effective for stuffy symptoms, pneumonia, bronchitis, headache, stiff shoulders, and high blood pressure. It is used for skin problems such as liver function, hyperemia, menstrual irregularities and acne.
  • Corolla is a flower of the annual herbaceous cocklecomb Celosia cristata , belonging to the amaranthaceae. Leaves are alternate, long, leafy, ovate or ovate lanceolate, pointed, 5-10cm long, 1-3cm wide, with bottom to be. Flowers bloom in July-August in red, yellow, and white, and fruits are egg-shaped, with 3-5 black seeds. Coronary artery is used for hemostatic purposes for ophthalmic diseases, hypermenstrual, uterine bleeding, and hemorrhage.
  • Kwandonghwa refers to the buds of the Tussilago farfara of the Asteraceae family and is also known as Kanto, Tongdong, Vomiting, Fairy Tales, Jedong, Chandong, Tong, and Lake.
  • Kwanhwa is used for cough, expectorant, sputum and pulmonary tuberculosis, lung abscess, and is used for external seawater, asthma, and the above-mentioned infectious disease.
  • Kwanhwa is effective in increasing respiratory secretions, antitussive action, respiratory excitability and light anxiety, vasoconstriction, acute bronchitis in children, bronchial asthma, and sore throat.
  • a lump is a bud of the Sophora japonica .
  • Necrosis is used to stop constipation, abortion, and hemostasis when eyeball hyperemia, intestinal bleeding, uterine bleeding, nosebleeds, bloody stool, and blood vomit due to liver fever. It is also effective for hypertension, headache, dizziness, arteriosclerosis, stroke, cerebral hemorrhage, and stuffy chest. Hemostasis, decreased capillary permeability, lowered blood pressure, lowered cholesterol, anticonvulsion, anti-ulcer, anti-radioactivity, frostbite treatment, It has a gentle action.
  • Gold and silver coins refer to the buds of Lonicera japonica or related plants. Gold and silver coins are used when the heat is lowered and the chest is thirsty and thirsty. It is good for inflammation, and it causes boils, skin toxins, organ inflammation, and pus. Also used for dysentery, skin tissue necrosis due to heat poisoning, mastitis. It is applied to colitis, gastric ulcer, cystitis, sore throat, tonsillitis, bronchitis, conjunctivitis and swelling, mumps and high fever, purulent infection. Gold and silver has antibacterial, anti-inflammatory, antipyretic, leukocyte phagocytosis, central nervous system excitability, serum cholesterol lowering, ulcer prevention effect.
  • a flower is a flower of the Prunus persica or Prunus davidiana . It has the ability of diuresis, blood, and stool, and treats several species, each, faeces, and dysmenorrhea.
  • Cactus is a flower of Hierochloe odorata , a perennial herbaceous plant belonging to the flower family. It is used to stop vomiting blood and nosebleeds and to relieve pain.
  • I mperata cylindrica It is a flower of the perennial herbaceous plant, I mperata cylindrica , which belongs to the flower family. Efficacy in bleeding, orthodoxy, hemostasis, and clear fever. It is used for the treatment of hemorrhage, nasal bleeding, and ulcers.
  • Magnolia is the flower of Mallowaceae Hibiscus syriacus . Magnolia cures intestinal bleeding, dysentery, whites and skin diseases.
  • Windproof flowers are flowers of the windpocampus ( Saposhnikovia divaricata ). Windproof flowers are white and hang on the end of the main stems and the branches of the branches. The flowering period is from July to August. Windproof shoes are used for the treatment of heart pain, extremity and fracture pain.
  • Balsam is a flower of Impatiens balsamina , an annual plant of the family Balsam. Balsam has been known to have inhibitory activity against chromophoric glucose, Pseudomonas aeruginosa, Typhoid bacillus, and Lycobacterium. It is mainly used for the treatment of urinary bleeding, post-birth blood, bruises, scabies, and intestines.
  • Pomegranate is a flower of the pomegranate (Pnica granatum ). Pomegranate is used for hemorrhage, bleeding due to nasal bleeding, otitis media, and bleeding.
  • Lilac is a flower of the Asteraceae Inula britannica .
  • the abdomen circulates and releases clumps, sputum, cough, hiccups, belching, asthma, chronic bronchitis, acute pleurisy, and chest pains as if it's always full.
  • Acupuncture has pharmacological effects such as anticonvulsant and diuretic effects of bronchus.
  • Narcissus is the flower of the perennial vine, Calystegia japonica . Flowers bloom in June-August, light red, with long stems on axillas, running one by one at the end. The two bracts under the calyx are green and heart-shaped. It is used to nourish the face, get rid of freckles on the face, and improve the appearance of the face.
  • Calendula is the flower of Pinus densiflora .
  • a male flower runs under several new branches of a male and female pine tree, elliptical, and brown.
  • Female flower runs 1 ⁇ 3 at the top and is ovate about 6mm long.
  • the pollen is characterized by a yellowish and sweet scent of light, and is mainly used to make food and smuggling, also called Songhwang.
  • a god is a magnolia denudata or a bud of the same plant. It is effective for treating cold energy and air congestion, sinusitis, runny nose, odorlessness, headache or lack of concentration, chills, fever, and sore cough. There is.
  • the god has astringent action, capillary dilation action, anti-inflammatory action, hypotensive action, analgesic, sedation, skin fungus and staphylococcus suppressing action.
  • Softening is a flower of the lotus Nymphaea nelumbo .
  • Lotus flower has the effect of bleeding, hemostasis, and moisturizing. It is used to treat bleeding and blisters caused by bruises.
  • the original painting refers to the buds of the Daphne genkwa .
  • Wonhwa is used for species to shed water in asthma, sea water and flanks. Also use only for abdominal swelling, boils, head rashes, urine, and stool.
  • Quikhwa means the flower of the mallow ( Althaea rosea ). Moisturization is used for white crabs, cold abdominal pain, inconspicuous pain, bleeding, uterine bleeding, burns, and redness of the nose. It has been reported to be effective against malaria.
  • Total flower is the flower of the allium fistulosum .
  • Appearance is umbel, flat spherical, muzzle is membranous, ovate or ovate lanceolate, 6 barks are lanceolate, white, a little shorter on outer side.
  • Totalization is used for the treatment of abdominal pain with nasal pain.
  • the phoenix is the flower of the Typha orientalis .
  • the female flower is 3 ⁇ 10cm long, hangs on the upper part, and has a stem on the ovary, and the pistil is similar to the spatula.
  • a male flower is yellow with a hair like a beard at the bottom.
  • the pollen lowers blood fever, convergence, and hemostatic action, which is used for keratosis, hemostasis, nosebleeds, urine bleeding, and uterine bleeding, and improves blood circulation.
  • the pharmacological action of turmeric has been reported, such as uterine excitement, lowering blood pressure, jingyeong, reduction of blood clotting time, tuberculosis bacterium growth, cholesterol lowering.
  • the safflower is a flower of the Asteraceae Carthamus tinctorius .
  • the pharmacological action of safflower is known to be effective in the contraction of the uterus and intestines through the excitement of smooth muscle, and is effective in lowering blood pressure, antagonizing blood coagulation, bruises, sprains and hay salt.
  • Safflower is effective in the use of blood, pain, pain, pain, aches and pains to treat amenorrhea, egg delivery, stillbirth, fish blood pain, carbuncles and bruises.
  • the "bean” is not limited in its kind, and specifically, Glycin max , Rhynchosia Nolubilis , Glycine max , Cheongtae ( Glycine max ), Emperor ( Glycine max ), Fence One selected from the group consisting of soybean ( Vicia faba ), kidney bean ( Phaseolus vulgaris ), haricot bean ( Phaseolus vulgaris ), red bean ( Vigna angularis ), soybean ( Phaseolus angularis ), bean sprouts ( Glycine max ) and soybean ( Glycine max ) It may be more than, but is not limited thereto.
  • the present invention includes a soybean extract or a fraction thereof as an active ingredient, wherein the soybean extract or a fraction thereof contains at least 700 ⁇ g / g of dipeptide having anti-inflammatory activity with respect to the total extract or fraction weight, anti-inflammatory It relates to a composition for.
  • the “bean extract” herein may be a crude extract of water, a C 1 -C 6 alcohol, and a solvent selected from the group consisting of combinations thereof.
  • the C 1 -C 6 alcohol may be specifically methanol or ethanol.
  • When the soybean is extracted with a solvent it is preferable to extract by adding a solvent corresponding to about 5 to 15 times the soybean, specifically, it is preferable to extract by adding about 10 times the solvent, but is not limited thereto.
  • the extraction may be a heat extraction, cold extraction, reflux cooling extraction, or ultrasonic extraction, and the like, there is no limitation if the extraction is obvious to those skilled in the art.
  • the extraction may be performed at room temperature, but for more efficient extraction, the extraction may be performed under heating conditions, preferably at about 40 to 100 ° C., more preferably at about 80 ° C., but is not limited thereto. It is not.
  • the extraction time is preferably about 2 to 4 hours, more preferably about 3 hours, but is not limited thereto, and may vary depending on conditions such as extraction solvent and extraction temperature.
  • the extraction may be extracted one or more times several times in order to obtain a larger amount of the active ingredient, preferably one to five times, more preferably three times the continuous extraction can be used combined extract.
  • the soybean extract may include a crude extract of soybean as described above, and may include the crude extract as a soluble fraction of an organic solvent obtained by further extracting the organic extract with a low polarity organic solvent. Hexane, methylene chloride, ethyl acetate, n-butanol, and the like may be used as the organic solvent, but is not limited thereto.
  • the extract extracted by the above method or a soluble fraction of the extract may be used as it is, but may be used in the form of an extract by concentrating after filtration, it may be used as a lyophilized form by lyophilization after concentration.
  • fraction of soybean extract refers to a component that has been separated through an additional fractionation process for soybean extract.
  • the fraction of the soybean extract is an ethyl acetate or butanol fraction for C 1 to C 5 alcohol extract, specifically, may be an ethyl acetate fraction.
  • anti-inflammatory activity means any kind of activity that inhibits or inhibits inflammation.
  • the anti-inflammatory composition of one aspect of the present invention can inhibit the stimulation source by 40% or more, as compared to the experimental group that does not have any treatment on the cells secreting interleukin.
  • the inhibition rate of the stimulus source is obtained by Equation 1 in the embodiment.
  • the anti-inflammatory activity of the present specification means activity showing an increased secretion amount of interleukin similar to or slightly higher than that of the experimental group which did not perform any treatment on cells secreting interleukin even by stimulation of a stimulus that secretes interleukin.
  • the soybean extract or a fraction thereof contains less than 700 ⁇ g / g of dipeptide having anti-inflammatory activity with respect to the total extract or fraction weight, dramatic anti-inflammatory activity may not be sufficiently observed.
  • the soybean extract or fractions thereof, the dipeptide having an anti-inflammatory activity based on the total extract or fraction weight, 700 ⁇ g / g or more, 750 ⁇ g / g or more, 800 ⁇ g / g or more, 850 ⁇ g / g
  • the soybean extract or a fraction thereof is a dipeptide having an anti-inflammatory activity 700g / g to 9000g / g, 750g / g to 9900g / g, 800g / g to 9800 with respect to the total extract or fraction weight ⁇ g / g, 850 ⁇ g / g to 9700 ⁇ g / g, 900 ⁇ g / g to 9600 ⁇ g / g, 950 ⁇ g / g to 9500 ⁇ g / g, 1000 ⁇ g / g to 9400 ⁇ g / g, 1050 ⁇ g / g to 9300 ⁇ g / g, 1100 ⁇ g / g to 9200 ⁇ g / g, 1150 ⁇ g / g to 9100 ⁇ g / g, 1200 ⁇ g / g to 9000 ⁇ g / g, 1250 ⁇ g / g to 8900 ⁇ g
  • An anti-inflammatory composition which is an aspect of the present invention, induces inhibition of one or more of the expression of interleukin-6, the expression of interleukin-8, and the expression of monocyte chemoattractant protein-1, thereby alleviating skin irritation or inflammation, and also retinoication. Skin irritation or inflammation caused by acid or sodium lauryl sulfate.
  • the dipeptide of the extract or fraction may be one or more of Glu-Phe and Glu-Tyr.
  • the weight ratio of Glu-Phe: Glu-Tyr included in the extract or fraction may be 0-50: 1, but is not limited thereto. Specifically, 1-45: 1, 1-40: 1, 1-35: It may be included in a weight ratio of 1, 1-30: 1, 1-25: 1 or 1-20: 1.
  • the extract or fraction may have an anti-inflammatory activity exhibiting a stimulus suppression rate of 40% or more compared to the untreated group.
  • Untreated group refers to an experimental group that has not been treated with cells that secrete interleukin. If the stimulus suppression rate of more than 40% compared to the untreated group, it can be seen to have an antimicrobial activity against inflammation.
  • the extract or fraction contained in the composition of the present invention is a stimulation source, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 100% or more, 110 More than 120%, more than 130%, more than 140%, more than 150%, more than 160%, more than 170%, more than 180%, more than 190%, or more than 200% of stimulus suppression.
  • the extract or fraction included in the composition of one aspect of the present invention 50 to 700%, 60 to 690%, 70 to 680%, 80 to 670%, 90 to 660%, 100 to 650 relative to the irritant %, 110-640%, 120-630%, 130-620%, 140-610%, 150-600%, 160-600%, 170-590%, 180-580%, 190-570%, 200-560 A percentage of stimulus inhibition may be indicated.
  • the extract shows a similar or slightly lower increase in the amount of interleukin secretion than the experimental group which did not undergo any treatment on cells secreting interleukin, even by stimulation of a stimulus that secretes interleukin.
  • the amount of interleukin secretion is increased by 150% or more compared with the amount of interleukin secretion of cells not treated with the stimulus even by stimulation of the stimulus that secretes interleukin.
  • the “stimulatory source” includes retinoic acid or sodium lauryl sulfate.
  • the beans include fermented soybeans.
  • Floral fermentation fermentation of the present specification may include, for example, fermenting soybeans in flowers, fermenting soybeans in petals, or fermenting together soybeans or crushed soybeans, but is not limited thereto. No, it is meant to include all instances of “fermenting together” legumes.
  • the extract or fraction may be contained in 0.001 to 30% by weight based on the total weight of the composition. If it is less than 0.001% by weight, the desired effect cannot be expected. If it exceeds 30% by weight, the increase of the effect is insignificant compared to the increase in content, and the formulation stability may be deteriorated.
  • the extract or fraction may be contained in 0.005 to 28% by weight, 0.01 to 26% by weight, 0.05 to 24% by weight, 0.1 to 22% by weight or 0.5 to 20% by weight relative to the total weight of the composition. have.
  • the flowers are brown, chrysanthemum, corolla, Kanto, lump, gold and silver, painting, homegrown, mother tree, knotweed, wheat dream, windproof, balsam, pomegranate, viola, narcissus, pine,
  • the god may be one or more selected from the group consisting of softening, wonhwa, quenhwa, gunhwa, huangpu and safflower.
  • the soybean may be one or more selected from the group consisting of frosted, Seomoktae, black Tae, chungtae, yellow, hedge beans, kidney beans, ground kidney beans, red beans, soybeans, bean sprouts beans and soybeans.
  • the composition may be for reducing interleukin secretion, the interleukin comprises interleukin-8 or interleukin-6.
  • the composition may be a pharmaceutical composition.
  • the pharmaceutical composition may be anti-inflammatory, and may be a pharmaceutical composition effective for anti-inflammatory action involving interleukin.
  • the composition When the composition according to the present invention is applied to medicines, the composition may be formulated into an oral or parenteral dosage form in the form of solid, semi-solid or liquid by adding a commercially available inorganic or organic carrier.
  • preparations for oral administration include tablets, pills, granules, capsules, powders, fine granules, powders, emulsions, syrups, pellets and the like.
  • preparations for parenteral administration include injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like.
  • the active ingredient of the present invention it can be easily formulated according to the conventional method, and surfactants, excipients, coloring agents, spices, preservatives, stabilizers, buffers, suspensions, and other commonly used auxiliaries can be suitably used.
  • composition according to the present invention may be administered orally, parenteral, rectal, topical, transdermal, intravenous, intramuscular, intraperitoneal, subcutaneous.
  • the dosage of the active ingredient will vary depending on the age, sex and weight of the subject to be treated, the specific disease or pathology to be treated, the severity of the disease or pathology, the route of administration and the judgment of the prescriber. Dosage determination based on these factors is within the level of skill in the art. Typical dosages are from 0.001 mg / kg / day to 2000 mg / kg / day, more specifically from 0.5 mg / kg / day to 1500 mg / kg / day.
  • the composition may be a health food composition.
  • the composition may be anti-inflammatory, and may be a health food composition effective for anti-inflammatory action involving interleukin.
  • composition according to the invention provides various types of food additives or functional foods comprising. It can be processed into fermented milk, cheese, yogurt, juice, probiotic and health supplement containing the composition, and can be used in the form of various other food additives.
  • the composition may contain other ingredients and the like that can give a synergistic effect to the main effect within a range that does not impair the main effect of the present invention.
  • it may further include additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers and synthetic polymer materials to improve physical properties.
  • additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers and synthetic polymer materials to improve physical properties.
  • supplementary ingredients such as water soluble vitamins, oil soluble vitamins, polymer peptides, polymer polysaccharides and seaweed extract may be further included.
  • the components may be appropriately selected and blended by those skilled in the art according to the formulation or purpose of use, and the amount of the additives may be selected within a range that does not impair the object and effect of the present invention.
  • the amount of the components added may range from 0.01 to 5% by weight, more specifically from 0.01 to 3% by weight, based on the total weight of the composition.
  • compositions according to the invention may be in various forms, such as solutions, emulsions, viscous mixtures, tablets, powders, and the like, which may be administered by various methods such as simple drinking, injection, spray or squeeze.
  • the composition may be a cosmetic composition.
  • the cosmetic composition is not particularly limited in formulation, and may be appropriately selected as desired.
  • softening cream skin lotion and milk lotion
  • nourishing cream essence
  • nourishing cream massage cream, pack, gel, essence
  • eye cream eye essence
  • cleansing cream cleansing foam
  • cleansing water cleansing water
  • pack powder
  • the cosmetic composition may include using the formulation of the external preparation for skin in the form of ointments, patches, and the like.
  • Cosmetic compositions according to the invention may be provided in all formulations suitable for topical application.
  • it may be provided in the form of a solution, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an aqueous phase in an oil phase, a suspension, a solid, a gel, a powder, a paste, a foam, or an aerosol composition.
  • Compositions of such formulations may be prepared according to conventional methods in the art.
  • the cosmetic composition according to the present invention may include other ingredients in addition to the above-mentioned substances within the range not impairing the main effect, preferably giving a synergistic effect to the main effect.
  • the cosmetic composition according to the present invention may further include a moisturizer, an emulsifier, a UV absorber, a preservative, a fungicide, an antioxidant, a pH adjuster, organic and inorganic pigments, flavors, coolants or limiting agents.
  • the blending amount of the above components can be easily selected by those skilled in the art within the range that does not impair the object and effect of the present invention, the blending amount may be 0.01 to 5% by weight, specifically 0.01 to 3% by weight based on the total weight of the composition have.
  • the present invention provides a method for producing an anti-inflammatory bean extract, the method
  • (c) relates to a manufacturing method comprising the step of extracting the fermented soybeans.
  • Fermenting the beans of step (b) with the flowers in the manufacturing method includes fermenting the beans wrapped in the flowers, or fermenting the beans with petals. none.
  • step (b) may be a step of fermenting soybeans with flowers at 5 to 40 °C for 3 to 10 days.
  • the extract of soybean when fermented under the above conditions, may contain a large amount of dipeptide. Specifically, when the fermentation is less than 5 °C, fermentation can not occur sufficiently, if the fermentation exceeds 40 °C soybean itself decay.
  • the temperature of the step of fermenting soybean may be 7 to 38 °C, 9 to 36 °C, 11 to 34 °C, 13 to 32 °C or 15 to 30 °C, more specifically can be fermented at room temperature have.
  • the fermentation period may be 4 to 9 days, 5 to 8 days or 6 to 7 days.
  • step (b) may be a step of fermenting the beans with a flower at room temperature for 3 to 10 days.
  • the said fermentation includes the step of leaving beans and flowers together in a container.
  • the anti-inflammatory activity of the extract can be excellent.
  • the said container contains an onggi.
  • the flower is brown, chrysanthemum, corolla, Kanto, lump, gold and silver, flower, homegrown, flower, woody, wheat dream, windproof, balsam, pomegranate, lined, line drawing It may be one or more selected from the group consisting of, songhwa, god, softening, wonhwa, quenization, sum total, huang and safflower.
  • the soybean may be one or more selected from the group consisting of frosted, seomoktae, blacktae, chungtae, yellow, hedge, kidney beans, ground kidney beans, red beans, soybeans, bean sprouts and soybeans. .
  • the present invention provides an effective amount of a composition comprising a soybean extract or a fraction thereof containing 700 ⁇ g / g or more of the dipeptide having an anti-inflammatory activity relative to the total extract or fraction weight to improve inflammation of the subject or To a method of treatment.
  • the present invention may be directed to an anti-inflammatory use of a composition comprising a soybean extract or a fraction thereof containing 700 ⁇ g / g or more of the dipeptide having anti-inflammatory activity with respect to the total extract or fraction weight.
  • the present invention may also be related to a soybean extract or a fraction thereof containing a dipeptide having an anti-inflammatory activity for use in amelioration or treatment of inflammation in an amount of 700 ⁇ g / g or more based on the total extract or fraction weight. .
  • Example 1 About 1 g of each sample prepared in Example 1 and Comparative 1 was taken, extracted with ultrasonic waves with 60 ° C. water for 30 minutes, and dispersed well. It was then filtered through a 0.2 ⁇ m PVDF membrane filter and 1 ⁇ l of each sample solution was injected into a high performance liquid chromatography / ultraviolet absorbance photometer and analyzed. Concentration measurement results of the analysis results are shown in Table 1 below.
  • Test cells keratinocytes (Cell name: HaCaT obtained from Dr. NE Fusenig, Liebes Krebsforschungstechnik, Heidelberg, Germany) and 10% fetal bovine serum (Ftal bovine sereum, FBS, obtained from Gibco, USA) and 1% Approximately 2 ⁇ 10 in 96 well plates using DMEM (Dulbecco's Modified Eagle Medium, Lonza, USA) medium containing Penicillin-Streptomycin (Gibco, USA) After dispensing at a density of 4 cells / well, the cells were incubated at 37 ° C. under 5% CO 2 conditions for 24 hours.
  • DMEM Dulbecco's Modified Eagle Medium, Lonza, USA
  • Penicillin-Streptomycin Gibco, USA
  • the cells were washed once with 200 ul of phosphate buffered saline (PBS), and 200 ul of DMEM medium containing fetal bovine serum was added and incubated for 24 hours.
  • PBS phosphate buffered saline
  • DMEM medium containing fetal bovine serum was added and incubated for 24 hours.
  • Glu-Phe Glu-Tyr and other dipeptide substances at 0.01% by weight in DMEM medium containing 1% fetal bovine serum for 10 minutes, retinoic acid (Sigma- Aldrich, USA) and further incubated for 24 hours.
  • Interleukin-induced retinoic acid using Interleukin-8 (IL-8), Monocyte chemoattractant protein-1 (MCP-1) ELISA kit (obtained by BD pharmigen, USA) -8 (Interleukin-8; IL-8) free inhibitory effect was measured and the results are shown in Table 2 below.
  • the inhibitory capacity was calculated based on the absorbance of Recombinant Interleukin-8, a standard material, to obtain a reaction formula between the absorbance and the standard material, and then substituted by the absorbance of the treated material to Interleukin-8 (Interleukin-8; The secretion amount of IL-8) was obtained. Thereafter, the stimulation relaxation rate was evaluated by Equation 1 below.
  • Stimulation alleviation rate (%) 100 x [1- (Increased IL-8 secretion in the retinoic acid and substance mixture group / IL-8 secretion increased in the retinoic acid alone group)]
  • Test cells keratinocytes (Cell name: HaCaT obtained from Dr. NE Fusenig, Liebes Krebsforschungstechnik, Heidelberg, Germany) and 10% fetal bovine serum (Fetal bovine sereum, FBS, obtained from Gibco, USA) and 1% Approximately 2 ⁇ 10 in 96 well plates using DMEM (Dulbecco's Modified Eagle Medium, Lonza, USA) medium incorporating Penicillin-Streptomycin (Gibco, USA) After dispensing at a density of 4 cells / well, the cells were incubated for 24 hours at 37 ° C. and 5% CO 2 .
  • DMEM Dulbecco's Modified Eagle Medium, Lonza, USA
  • Penicillin-Streptomycin Gibco, USA
  • the cells were washed once with 200 ul of phosphate buffered saline (PBS), and 200 ul of DMEM medium containing fetal bovine serum was added and incubated for 24 hours.
  • PBS phosphate buffered saline
  • DMEM medium containing fetal bovine serum was added and incubated for 24 hours.
  • Glu-Phe Glu-Tyr and other dipeptide materials with 0.01% concentration for 10 minutes with DMEM medium containing 1% fetal calf serum, further treatment with 10 ppm sodium lauryl sulfate and incubated for 24 hours. I was.
  • the inhibitory capacity was calculated based on the absorbance of Recombinant Interleukin-6, which is a standard, to obtain a reaction formula between the absorbance and the standard. Then, the absorbance of the treated material was substituted for Interleukin-6; The secretion amount of IL-6) was obtained. Since the stimulation relaxation rate was evaluated by the following equation (2).
  • Stimulation alleviation rate (%) 100 x [1- (Increased IL-6 secretion in the sodium lauryl sulfate and substance mixture group / IL-6 secretion in the sodium lauryl sulfate alone group)]
  • soybean extract-containing composition according to the present invention is applicable to various formulations as follows, but is not limited thereto.
  • soybean extract of Example 1 100 mg of soybean extract of Example 1, soybean extract 50 mg, soybean oil 180 mg, red ginseng extract 50 mg, palm oil 2 mg, palm hardened oil 8 mg, lead 4 mg and lecithin 6 mg, 1 capsule according to a conventional method 400 mg of sugar was added to prepare a soft capsule.
  • soybean extract of Example 1 100 mg of soybean extract of Example 1, 50 mg of soy extract, 100 mg of glucose, 50 mg of red ginseng extract, 96 mg of starch and 4 mg of magnesium stearate and 40 mg of 30% ethanol were added to form granules, followed by 60 It was dried at ⁇ ⁇ and compressed into tablets using a tablet press.
  • soybean extract of Example 1 100 mg of soybean extract of Example 1, 50 mg of soy extract, 100 mg of glucose, 50 mg of red ginseng extract and 600 mg of starch were mixed and 100 mg of 30% ethanol was added to form granules, followed by drying at 60 ° C. Formed and filled into fabric. The final weight of the content was 1 g.
  • soybean extract of Example 1 100 mg of soybean extract of Example 1, 50 mg of soy extract, 10 g of glucose, 50 mg of red ginseng extract, 2 g of citric acid and 187.8 g of purified water were mixed and filled into bottles. The final dose of the contents was 200 ml.
  • composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method.
  • the granules may be prepared and used for preparing a health food composition according to a conventional method.
  • Citric Acid ... .... 1000 mg
  • the resulting solution is filtered and obtained by sterilization in a sterilized 2 L container, sealed sterilization and then refrigerated and stored in the present invention For the preparation of healthy beverage compositions.
  • Soybean Extract of Example 1 0.0025 glycerin 8.0 Butylene glycol 4.0 Liquid paraffin 45.0 Beta Glucan 7.0 Carbomer 0.1 Caprylic / Capric Triglycerides 3.0 Beeswax 4.0 Cetearyl Glucoside 1.5 Sesqui oleic acid sorbitan 0.9 Vaseline 3.0 paraffin 1.5 Preservative, coloring, flavoring Quantity Purified water Remaining amount
  • composition comprising the extract of Ssam fermented soybean extract of the present invention contains extremely high content of dipeptides, thereby reducing the secretion of interleukin for stimulation, and thus anti-inflammatory and skin irritation compared to general soybean extract or general soybean fermented extract. Efficacy in alleviation, and can be used in various fields such as cosmetics and medicines.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition anti-inflammatoire comprenant un extrait de haricot ou sa fraction en tant que principe actif, et plus particulièrement une composition comprenant ledit extrait de haricot ou sa fraction, incluant un dipeptide qui possède une activité anti-inflammatoire.
PCT/KR2013/003236 2012-04-26 2013-04-17 Composition anti-inflammatoire comprenant un extrait de haricot utilisant la fermentation-cataplasme de fleur, et son procédé de préparation WO2013162202A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120043617A KR20130120597A (ko) 2012-04-26 2012-04-26 꽃 쌈발효에 의한 항염증용 콩 추출물을 포함하는 조성물 및 제조방법
KR10-2012-0043617 2012-04-26

Publications (1)

Publication Number Publication Date
WO2013162202A1 true WO2013162202A1 (fr) 2013-10-31

Family

ID=49483439

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/003236 WO2013162202A1 (fr) 2012-04-26 2013-04-17 Composition anti-inflammatoire comprenant un extrait de haricot utilisant la fermentation-cataplasme de fleur, et son procédé de préparation

Country Status (2)

Country Link
KR (1) KR20130120597A (fr)
WO (1) WO2013162202A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103893593A (zh) * 2014-04-03 2014-07-02 梁卫 具有清热解毒、抗炎和增强免疫力作用的药物组合物
CN104982919A (zh) * 2015-04-30 2015-10-21 新昌县大成生物科技有限公司 一种发酵槐花粉的制备方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102299276B1 (ko) * 2014-07-16 2021-09-09 (주)아모레퍼시픽 납떼기콩 오일을 포함하는 조성물
KR102017132B1 (ko) 2018-10-11 2019-09-03 임승호 실론시나몬나무껍질 및 구릿대의 혼합발효추출물을 함유하는 화장료 조성물
KR102173430B1 (ko) 2018-10-12 2020-11-03 고려은단주식회사 도라지 복합발효추출물과 식물추출물을 포함하는 항염 조성물 및 그 제조방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030032483A (ko) * 2001-10-18 2003-04-26 롯데제과주식회사 항염증 효능을 갖는 카카오 콩 또는 콩껍질 분획물
EP2106791A1 (fr) * 2008-03-31 2009-10-07 Biotempt B.V. Glutamine ou dipeptide contenant de la glutamine avec une posologie spécifique pour le traitement des inflammations
WO2011007612A1 (fr) * 2009-07-13 2011-01-20 不二製油株式会社 Agent anti-inflammatoire pour application orale, et peptide anti-inflammatoire pour application orale
KR20110112231A (ko) * 2010-04-06 2011-10-12 (주)아모레퍼시픽 약용 잎을 활용한 쌈 발효법 및 이를 활용한 피부 외용제 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030032483A (ko) * 2001-10-18 2003-04-26 롯데제과주식회사 항염증 효능을 갖는 카카오 콩 또는 콩껍질 분획물
EP2106791A1 (fr) * 2008-03-31 2009-10-07 Biotempt B.V. Glutamine ou dipeptide contenant de la glutamine avec une posologie spécifique pour le traitement des inflammations
WO2011007612A1 (fr) * 2009-07-13 2011-01-20 不二製油株式会社 Agent anti-inflammatoire pour application orale, et peptide anti-inflammatoire pour application orale
KR20110112231A (ko) * 2010-04-06 2011-10-12 (주)아모레퍼시픽 약용 잎을 활용한 쌈 발효법 및 이를 활용한 피부 외용제 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KANG, HUI JU ET AL.: "Metabolomic analysis ofmejo during fermentation by ultra performance liquid chromatography-quadrupole-time of flight mass spectrometry(UPLC-Q- TOF MS)", FOOD CHEMISTRY, vol. 127, 2011, pages 1056 - 1064 *
YOUNG, D. ET AL.: "Soy-derived di- and tripeptides alleviate colon and ileum inflammation in pigs with dextran sodium sulfate-induced colitis", THE JOURNAL OF NUTRITION, vol. 142, 21 December 2011 (2011-12-21), pages 363 - 368 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103893593A (zh) * 2014-04-03 2014-07-02 梁卫 具有清热解毒、抗炎和增强免疫力作用的药物组合物
CN104982919A (zh) * 2015-04-30 2015-10-21 新昌县大成生物科技有限公司 一种发酵槐花粉的制备方法

Also Published As

Publication number Publication date
KR20130120597A (ko) 2013-11-05

Similar Documents

Publication Publication Date Title
WO2015133710A1 (fr) Composition de shampooing contenant des extraits de plantes sauvages et d'herbes médicinales naturelles
KR100772575B1 (ko) 생약성분 추출물을 함유하는 피부 외용제 조성물
KR101702056B1 (ko) 피부세포증식 촉진, 항산화 및 항알러지 효과가 우수한 알로에 베라 새순 농축물 또는 추출물
WO2013162202A1 (fr) Composition anti-inflammatoire comprenant un extrait de haricot utilisant la fermentation-cataplasme de fleur, et son procédé de préparation
KR102033088B1 (ko) 식물 추출 혼합물을 포함하는 항균, 항염, 항산화, 피지분비억제 및 피부염 개선용 조성물
KR20150086982A (ko) 원지 추출물을 유효성분으로 함유하는 아토피 피부염의 예방 또는 치료용 조성물
KR102300581B1 (ko) 식물추출물 또는 이의 분획물을 유효성분으로 함유하는 피부 상태 개선용 조성물
KR102214985B1 (ko) 식물추출물 또는 이의 분획물을 유효성분으로 함유하는 피부 상태 개선용 조성물
WO2018111042A2 (fr) Composition cosmétique comprenant un extrait de plantes médicinales en tant qu'ingrédient actif
KR20160128589A (ko) 천연 추출물을 포함하는 염증성 피부질환 개선용 조성물
WO2020138834A1 (fr) Composition pour la prévention ou le traitement de maladies de la peau comprenant de la spirée couronne de mariée
KR101891218B1 (ko) 천연 추출물을 포함하는 피부염 질환의 치료용 조성물
KR101157535B1 (ko) 아토피성 피부염 개선제 조성물
KR102049278B1 (ko) 자귀나무 수피 추출물을 유효성분으로 함유하는 항균 활성을 가지는 조성물 및 이를 포함하는 여성청결제 조성물
WO2019231244A1 (fr) Composition de savon et savon comprenant ladite composition
WO2020059906A1 (fr) Composition comprenant un extrait de cinnamomum aromaticum, de lonicera japonica, d'elsholtzia ciliata, de schisandra chinensis, d'arctium lappa et de paeonia suffruticosa pour la prévention ou le traitement du vieillissement cutané ou de la dermatite et procédé utilisant celle-ci
KR20190138518A (ko) 꿩의다리 추출물을 포함하는 구강질환 예방 또는 치료용 조성물
KR101189794B1 (ko) 양마 추출물을 함유하는 피부 외용제 조성물
KR20090075950A (ko) 난치성 아토피성 피부염 치료용 조성물
KR101594034B1 (ko) 덤불쑥, 알꽈리 및 동백나무잎 복합추출물을 함유하는 항피부알러지, 항염증및 노인성 체취 제거용 조성물
KR20180017974A (ko) 복합생약추출물을 유효성분으로 함유하는 여드름 예방 또는 치료용 화장료 조성물
KR102027453B1 (ko) 포제 추출물을 포함하는 조성물
KR102014965B1 (ko) 포제 추출물을 포함하는 조성물
WO2023022272A1 (fr) Composition fonctionnelle contenant des orties et sa méthode de préparation
KR102026343B1 (ko) 명아주 추출물 및 참마 추출물을 포함하는 화장료 조성물 및 이의 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13781236

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 18/03/2015)

122 Ep: pct application non-entry in european phase

Ref document number: 13781236

Country of ref document: EP

Kind code of ref document: A1